Imitation of normal plasma growth hormone profile by subcutaneous administration of human growth hormone to growth hormone deficient children

1983 ◽  
Vol 102 (1) ◽  
pp. 6-10 ◽  
Author(s):  
J. Sandahl Christiansen ◽  
H. Ørskov ◽  
C. Binder ◽  
K. W. Kastrup

Abstract. The time course of plasma growth hormone (hGH) levels following sc and im injection of hGH was studied in 12 children with growth hormone deficiency who had received long-term treatment with im injections of highly purified hGH. Also the spontaneous diurnal GH levels in 8 normal children of comparable age were recorded. Blood samples were obtained during 24 h after im and sc injections of 4 IU/m2 hGH and analysed for immunoreactive hGH. While a median peak value of 160 ng/ml (range 135 to 475 ng/ml) was obtained 2 h after im injection, sc injection resulted in a more sustained elevation reaching 41 ng/ml (range 32 to 51 ng/ml) at 6 h subsiding slowly with a median concentration of 15 ng/ml (range 5–24 ng/ml) persisting after 14 h. Gel chromatography demonstrated that the hGH immunoreactivity of blood samples obtained as late as 14 h after sc injection had unaltered molecular size. Seven of the patients were further studied after sc injection of 2 IU/m2 at 20.00 h instead of in the morning. A plasma profile was attained during the night which roughly approximated the average nocturnal plasma pattern of the normal children.

PEDIATRICS ◽  
1971 ◽  
Vol 48 (6) ◽  
pp. 946-954
Author(s):  
Louis E. Underwood ◽  
Kazuo Azumi ◽  
Sandra J. Voina ◽  
Judson J. Van Wyk

Plasma growth hormone levels were determined from samples drawn at 15-minute intervals during the first 2 hours of spontaneous, nocturnal sleep in 16 normal children, one nongrowth hormone deficient dwarf, and three children with hypopituitarism. Depth of sleep was assessed by continuous EEC monitoring. Daytime growth hormone responses to insulin-induced hypoglycemia were also assessed in most of these children and in a larger group of normal and hypopituitary children. In the normal children and in the nongrowth hormone deficient dwarf, increases in plasma growth hormone after the onset of the slow wave pattern on EEG were equivalent to those seen after insulin-induced hypoglycemia. No significant changes in growth hormone levels were seen in the hypopituitary patients. Interpretation of growth hormone levels in blood specimens obtained by serial sampling after the onset of deep sleep appears to be as reliable a method of assessing pituitary function as the levels resulting from insulin-induced hypoglycemia. Although growth hormone analysis of a single sample taken about 1 hour after the onset of deep sleep should exclude the diagnosis of growth hormone deficiency in as many as 70% of the nongrowth hormone deficient individuals, a positive diagnosis of hyposomatotropism must be based on either serial sampling during deep sleep or challenge with insulin and/or arginine.


1985 ◽  
Vol 108 (1) ◽  
pp. 11-19 ◽  
Author(s):  
K. Takano ◽  
N. Hizuka ◽  
K. Shizume ◽  
N. Honda ◽  
N. C. Ling

Abstract. Synthetic human pancreatic GRF (hpGRF-44) was administered sc to 8 normal children with short stature and 11 patients with GH deficiency. After a dose of 100–200 μg hpGRF-44, mean plasma GH levels reached a peak at 15 min of 27.2 ± 6.4 (± se) ng/ml in normal children. However the responses were variable and peak plasma GH varied from 10.1 to 56.5 ng/ml. Eight of 11 patients with idiopathic GH deficiency did not respond to sc administration of 100–300 μg hpGRF-44. However, a plasma GH increase of more than 5 ng/ml occurred in 2 patients and to twice the basal level in 1 patient. Their GH values were 14.3, 5.2 and 3.4 ng/ml, respectively. After repetitive administration of hpGRF-44 (200 μg, twice a day) sc for 5 consecutive days, 2 of 8 patients restored their responsiveness, but the remaining patients did not show GH rise in response to both sc and iv bolus administration of hpGRF-44. Repetitive hpGRF-44 administrations for 5 days had no effect on somatomedin-C production.


1986 ◽  
Vol 113 (4_Suppl) ◽  
pp. S118-S122 ◽  
Author(s):  
O. BUTENANDT ◽  
M. EMMLINGER ◽  
H. DOERR

Abstract 38 patients with proven growth hormone deficiency (GHD) and 19 children with familial short stature received an iv GRF-bolus injection of 1 ug/kg body weight. Whereas in all control children plasma growth hormone rose significantly (mean of maximal values 36 ng/ml), only 7 out of 38 patients with GHD reached peak values of 8 ng/ml or more. GRF-priming by 1 ug GRF/kg BW given once daily s.c. for 5 days in 19 patients improved the response of the pituitary gland in 11. Thus, following the first GRF test, only 21 % of patients demonstrated function of the pituitary gland whereas 45 % did so when all test results are combined. To evaluate the pituitary function in patients with GHD correctly, GRF tests following a GRF priming period seems to be necessary to reactivate atrophic somatotropic cells of the pituitary gland.


1985 ◽  
Vol 22 (1-2) ◽  
pp. 32-45 ◽  
Author(s):  
Guy Van Vliet ◽  
Danièle Bosson ◽  
Claude Robyn ◽  
Margareta Craen ◽  
Paul Malvaux ◽  
...  

PEDIATRICS ◽  
1974 ◽  
Vol 53 (6) ◽  
pp. 929-937
Author(s):  
S. Douglas Frasier

No suggested screening test meets all of the criteria set for such a procedure. The minimum incidence of a positive response in normal children detected in a single blood sample after diethylstilbestrol, sleep or exercise is approximately 70%. This is higher than that observed when a single sample is obtained following oral glucose. While both sleep and exercise are physiologic stimuli, the former may be quite inconvenient unless an outpatient facility staffed with appropriate personnel is available. An exercise test employed in the office may well be the best screening procedure for the practicing physician. The optimal criteria for a definitive test of growth hormone function are also not met by any single stimulus. Insulin-induced hypoglycemia, arginine infusion, intramuscular glucagon and oral 1-DOPA are all useful procedures. None alone discriminate completely between the normal and the growth hormone-deficient child. Despite potential hazards, insulin-induced hypoglycemia remains the standard against which other stimuli are judged. Arginine and 1-DOPA appear to be equally effective. The literature contains insufficient data to allow adequate evaluation of intramuscular glucagon alone, and the results of combined propranolol-glucagon stimulation, while promising, require confirmation. Because of an inconstant and/or small magnitude of response leading to results which are difficult to interpret, the use of glucose, pyrogen, vasopressin and ACTH are not adequate tests of growth hormone function. Bovril® is a satisfactory stimulus for those children who will take it. Those factors which modify the growth hormone response must be considered in evaluating the results of stimulation tests. Blunted responses should be interpreted with extreme caution in the obese child. A fasting growth hormone concentration ≥ 7 ng/ml is presumptive evidence of intact growth hormone function regardless of the subsequent response to stimulation. It is essential that patients be euthyroid in order to interpret the results of growth hormone function tests. Physiologic glucocorticoid replacement therapy should not confuse the interpretation of results. Whether or not pretreatment with sex steroids is worthwhile in the routine evaluation of children for suspected growth hormone deficiency is an open question. Although it is agreed that the definitive diagnosis of growth hormone deficiency depends on the demonstration of failure to respond to two stimuli, which two are most satisfactory is not settled. The sequential administration of arginine and insulin on the same day appears to limit significantly the incidence of false-positive laboratory diagnoses of growth hormone deficiency. The significance of intermediate values in response to stimulation remains unclear. Caution should be exercised in assigning a child to the category of partial growth hormone deficiency. This question must be answered ultimately by the response to HGH therapy in the individual patient. Finally, several points should be kept in mind. All of the tests described depend on the detection and quantitation of immunologically active HGH and biological activity is not necessarily associated with the material(s) being measured. Since many of the stimuli used in the evaluation of growth hormone function are clearly pharmacologic, the physiological significance of the response to such stimuli must be interpreted with caution. The best current evidence suggests that all of the stimuli described act through an intact hypothalamus and pituitary. Differentiation between hypothalamic and pituitary sites of defective growth hormone function awaits the availability of growth hormone-releasing factor(s).


1984 ◽  
Vol 58 (2) ◽  
pp. 236-241 ◽  
Author(s):  
KAZUE TAKANO ◽  
NAOMI HIZUKA ◽  
KAZUO SHIZUME ◽  
KUMIKO ASAKAWA ◽  
MEGUMI MIYAKAWA ◽  
...  

2011 ◽  
Vol 57 (5) ◽  
pp. 30-37
Author(s):  
I I Dedov ◽  
V A Peterkova ◽  
T Iu Shiriaeva ◽  
E V Nagaeva ◽  
N N Volevodz ◽  
...  

The objective of the present study was to evaluate the efficacy and safety of the application of the new soluble pharmaceutical form of Rastan for subcutaneous injections at a dose of 15 IU/ml and compare its action with that of Rastan lyophilisate, 4 IU, designed to prepare solutions for subcutaneous administration. The two dosage forms are used to treat children suffering from growth hormone deficiency. The study included patients at the age from 4 to 12 years presenting with idiopathic growth hormone deficiency; they were randomized into two groups. During the first three months, the patients of both groups were treated with different pharmaceutical forms of recombinant growth hormone (rGH). The children in group 1 were given Rastan for subcutaneous injections and those in group 2 received Rastan lyophilysate for the preparation of solutions for the subcutaneous administration. Either form of GH was used at an equal daily dose of 0.033 mg/kg b.w. The patients of both groups showed marked improvement of the parameters of linear growth within the first three months. The difference in the growth rates was not significantly different between the two groups which suggests the identical effect of the two forms of rGH. During the next 9 months when the patients of both groups were treated only with the rGH for subcutaneous injections, the absolute growth response, height SDS, and the level of insulin-like growth factor 1 (IGF-1) continued to increase. It points out to the stable growth-promoting effect of Rastan for subcutaneous injections. No clinically significant abnormal changes in the results of complete blood cell count and biochemical analysis of blood were apparent during 12 months of therapy with this form of rGH. The same was true of the levels of free T4, cortisol, and prolactin in the blood. No adverse effects attributable to the therapy with rGH were documented.


1994 ◽  
Vol 131 (3) ◽  
pp. 313-318 ◽  
Author(s):  
Nisar A Pampori ◽  
Bernard H Shapiro

Pampori NA, Shapiro BH. Testicular regulation of sexual dimorphisms in the ultradian profiles of circulating growth hormone in the chicken. Eur J Endocrinol 1994;131:313–318. ISSN 0804–4643 Ultradian patterns in plasma growth hormone (GH) concentrations were determined in adult white Leghorn roosters, hens and capons. Serial blood samples were collected every 15 min over 8 h through surgically placed chronic indwelling right atrial catheters and assayed for GH content by a homologous radioimmunoassay. In both sexes, GH levels fluctuated episodically, with peak and interpeak periods each lasting about 45 min in both roosters and hens. However, GH concentrations in the peaks and nadirs were 2.5–3.5 times greater in the plasma GH profiles of roosters as compared to hens, which resulted in roosters having higher mean GH concentrations. Caponizing completely feminized the episodic GH secretory profile. In contrast to chickens, the common sexually dimorphic feature in secretory GH profiles of mammals is the enhanced peak frequencing found in females. Bernard H Shapiro, Laboratories of Biochemistry, School of Veterinary Medicine, University of Pennsylvania, 3800 Spruce Street, Philadelphia, PA 19104-6048, USA


1985 ◽  
Vol 110 (2) ◽  
pp. 145-151 ◽  
Author(s):  
Susan M. Webb ◽  
John A. H. Wass ◽  
Erica Penman ◽  
M. Murphy ◽  
José Serrano ◽  
...  

Abstract. Plasma immunoreactive somatostatin (IRS) levels were measured fasting at 09.00 h in groups of adult individuals and children of different ages, as well as in pregnant women, in patients with pernicious anaemia documented to be achlorhydric, and in children with growth hormone deficiency. There was a gradual rise in the mean level of IRS from the third decade (mean 35.8 ± 3.8 pg/ml), which reached significance at the seventh (61.1 ± 8.4 pg/ml), eighth (66.7 ± 5 pg/ml) and ninth decade (82.6 ± 13.8 pg/ml). No change was observed in the second 28.3 ± 3.8 pg/ml) and third (31.1 ± 3.2 pg/ml) trimester of pregnancy when compared with matched, non-pregnant controls (29.7 ± 2.2 pg/ml); however, the children aged under 2 years (69.6 ± 11.2 pg/ml) had significantly higher values than the eldest group (12 to 16 years old) (46.3 ± 7.2 pg/ml) (P < 0.05). In achlorhydric patients, basal (27.2 ± 3.7 pg/ml; P < 0.01) and postprandial IRS (42.8 ± 7.7 pg/ml; P < 0.001) was significantly lower than in a matched, normal control group (basal 59.4 ± 7.2; postprandial 132.1 ± 26.3 pg/ml). Growth hormone deficiency was not associated with any differences in circulating IRS, basally or after insulin hypoglycaemia, when compared with values in normal children. These results would suggest, 1) that age has a significant effect on plasma IRS, and should be considered in the interpretation of fasting plasma levels of IRS; 2) that pregnancy and growth hormone deficiency is not accompanied by any changes in circulating IRS and presumably, somatostatin binding proteins; 3) that gastric acid is necessary for a normal release of IRS from the gastrointestinal tract to the circulation.


Sign in / Sign up

Export Citation Format

Share Document